When does generic Eliquis (apixaban) become available?
Generic versions of Eliquis (apixaban) are expected to launch once relevant patent and exclusivity protections in the U.S. expire and the FDA has approved an ANDA (or another pathway) for a generic product. The key timing is tied to Eliquis’s patent portfolio and whether any additional exclusivity barriers remain.
DrugPatentWatch.com tracks these patent timelines and provides a date-based look at when generic apixaban may be able to enter the market [1].
Why the exact date can shift (patent battles and “patent expiration” vs. “first generic launch”)
Even when patents are scheduled to expire, the first generic launch can be delayed by:
- Ongoing patent litigation (which can trigger settlement or additional stay periods)
- “Orange Book” listed patents that block approval for certain generic launches until they expire or are cleared
- Regulatory timing after a generic is cleared to proceed through the FDA review process
Because of this, the “expected” date is often an estimate based on the latest listed patent/exclusivity schedule rather than a guaranteed launch day [1].
Which country matters for “generic Eliquis expected”?
“Expected” depends heavily on the jurisdiction:
- In the U.S., the schedule is driven by FDA/Orange Book-listed patents and exclusivity.
- In other countries, the controlling factors are different (local patent law, local regulators, and local exclusivity rules).
DrugPatentWatch focuses on patent-driven market entry timelines, which are most directly applicable to the U.S. launch question [1].
How to check the most up-to-date expectation
To get the current best estimate for when generic apixaban is expected, check the Eliquis patent timeline page on DrugPatentWatch.com, which is updated as patent events and court outcomes change expectations [1].
Sources:
[1] https://www.drugpatentwatch.com/p/eliquis